Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer
The leadership additions support the company's continued ability to scale as it delivers the right care model for women's health and family building
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause.
'Progyny has established itself at the forefront of building and delivering the right care model for women's health and family building. As we continue down the path of growth and innovation, we are intentional about bringing in visionary leaders who can accelerate our momentum and expand our impact,' said Pete Anevski, CEO, Progyny. 'Melissa and Geoffrey bring the healthcare industry expertise and passion that will power and scale the next stage of our superior solutions and services.'
Cummings is a strategic, data-driven leader with a deep understanding of healthcare operations and a proven track record in general management, payer operations, and customer experience. Her impressive 30-year career in healthcare, includes serving most recently as Executive Vice President and Chief Customer Officer at Blue Cross & Blue Shield of Rhode Island, and prior to that as Vice President, Strategic Product Solutions at Aetna.
'There's never been a more important time to rethink how women and families have traditionally been supported throughout their health journeys,' said Cummings. 'Progyny's unique model, unparalleled clinical outcomes, and commitment to high-touch care are setting a new standard in healthcare. I'm honored to join at such a transformative point in the company's journey, and I'm excited to help scale its mission and impact even further.'
Complementing Cummings' experience is Clapp who brings more than two decades of experience in healthcare technology, start-up innovation, engineering, and product development. As a Senior Vice President as well as Head of Strategy, Optum Health Solutions, he drove innovation that helped significantly increase earnings for both the Renal Care and Organ Transplant products, rebuilding them from the ground up. At Progyny, Clapp will lead product development and strategy and define the development roadmap for scalable, high-impact solutions that expand access to critical family building and women's health care.
"There are few companies out there that have the passion and resources to impact the women's health space at scale,' said Clapp 'I'm excited to bring my years of experience in leading product to Progyny, where we're anticipating what members will need tomorrow while delivering meaningful impact today.'
These appointments come at a time of significant momentum for Progyny. The company now serves more than 530 leading employers with 6.7 million contracted lives, offering solutions that span the reproductive health journey. With the latest addition of its Parent and Child Well-being program and doula support, Progyny continues to evolve into a single, trusted solution delivering value-based care, clinical excellence, and consistently superior outcomes.
For more information about Progyny's leadership and integrated solutions, visit www.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:James Hartinvestors@progyny.com
Media:Alexis Fordmedia@progyny.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on EHang (EH): 'I'm Not Going to Really Want to Do a Lot of China Right Now'
We recently published a list of . In this article, we are going to take a look at where EHang Holdings Limited (NASDAQ:EH) stands against other stocks that Jim Cramer discusses. A caller asked for Cramer's opinion on EHang Holdings Limited (NASDAQ:EH), and he said: 'You know, I'm not going to really want to do a lot of China right now. I think that the President and China, just don't feel that, I just don't, I'm not getting that vibe, you know what I mean?' EHang (NASDAQ:EH) develops and sells autonomous aerial vehicles and related systems for use in passenger transport, logistics, urban management, and aerial media. The company offers aircraft models, flight control technology, operational software, vertiports, and charging infrastructure for electric vertical takeoff and landing operations. A modern commercial jet airliner decorated with the company logo in flight against a clear blue sky. On May 27, BofA reduced the price target on EHang (NASDAQ:EH) from $26 to $24 and maintained a Buy rating after the company missed expectations in the first quarter due to weaker sales. Taking the first-quarter performance into account, the firm lowered its volume sales projections for 2025 and 2026 by 7% and 8%, and revised its non-GAAP net profit estimates for those years down by 63% and 12%, respectively. Overall, EH ranks 11th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of EH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, June 8, 2025
Everything to Know about Macro and Markets Stocks clocked in large weekly gains, returning to positive territory year-to-date. The Dow Jones Industrial Average (DJIA) rose by 1.17%, the S&P 500 (SPX) increased by 1.50%, and the tech-heavy Nasdaq-100 (NDX) gained 1.97% for the week. The S&P 500 finished more than 20% above April's low, reclaiming the 6,000 mark first reached in February, although it remained about 2% shy of its record high. Confident Investing Starts Here: Macro Steers the Markets The week began on a positive note, losing some steam in the second half. The weakness in PMI reports – with the manufacturing activity contracting for a third month in a row and services activity shrinking for the first time in 11 months – infused some gloom. However, Friday saw stocks find their footing again on solid job gains, which allayed fears about an imminent economic downturn. U.S. jobs growth stayed strong in May, climbing 139,000 with unemployment unchanged at 4.2%. Although the March and April reports were revised downward, May's report reassured investors, as it reflected a very gradual cooling of the labor market. Still, diving into the job report's details, a stronger-than-expected wage growth continues to put a floor under inflation. This supports the Federal Reserve's 'wait and see' stance, despite President Trump's demands for a cut. According to the CME FedWatch Tool, the chances of a June cut are nil, and July's rate decrease looks increasingly improbable. Prices in interest rate futures markets imply that investors expect two quarter-point rate cuts by year-end, with the first cut not expected until September. Wrapping Up the Season Despite tariff headwinds and macro volatility, S&P 500 companies delivered solid results last quarter. Index members reported 12.9% year-over-year earnings growth – the second straight double-digit increase. 78% of firms – above the five-year average – exceeded EPS estimates. However, the number of companies issuing negative EPS guidance (68) was also above the average. In Q1, the Healthcare sector reported the highest earnings growth, 43%, leaving the Magnificent Seven cohort's 27.7% increase in the dust. In fact, Mag 7's earnings growth rate was below the average (32.1%) of the previous three quarters. Still, three members of the Magnificent bunch – Alphabet (GOOGL), Amazon (AMZN), and Nvidia (NVDA) – are among the top five contributors to earnings growth for the S&P 500 for the first quarter. Interestingly, Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) were the other top contributors. Stocks That Made the News ▣ Tesla (TSLA) lost nearly 15% over the week following the ugly social media spat between Elon Musk and President Donald Trump. The feud flared up over the impending budget bill, with Musk calling it 'disgusting', and followed by Trump's threat to take away billions of dollars in government subsidies and contracts awarded to Musk's businesses. Although shares rebounded on Friday as Musk and Trump moved to cool tensions, the spat cost Tesla over $150 billion loss in market cap. ▣ Broadcom (AVGO) fell on Friday, wiping out its weekly gain, after the chip giant only narrowly surpassed analyst revenue and expectations. In addition, its current quarter revenue guidance was also just above consensus. Solid, but not a blowout quarter and outlook, weighed on shares that recently hit all-time highs. Still, the company delivered on the AI narrative, reporting surging demand and upping AI networking revenue guidance. ▣ Microsoft (MSFT) continued its climb, hitting a fresh record on Friday as analysts raised price targets on acceleration in Azure and AI-related revenue growth. According to Goldman Sachs, Microsoft's cloud revenue could more than double by 2029. The tech leader's market cap has reached $3.5 trillion, surpassing that of Nvidia (NVDA) and making MSFT the largest company in the world. ▣ Lululemon (LULU) shares dove by 20% on Friday, capping large weekly losses, despite earnings beat. The apparel retailer cut guidance on macroeconomic uncertainty and the impact of tariffs that might force LULU to increase prices. ▣ DocuSign (DOCU) was another notable decliner, sinking nearly 19% post earnings. The company reported a strong financial performance, but a miss on billings raised investor fears about future growth. The Q1 2025 earnings season is practically over, but several notable earnings releases are still scheduled for the next few days. These include Casey's General (CASY), Oracle (ORCL), Chewy (CHWY), and Adobe (ADBE).
Yahoo
2 hours ago
- Yahoo
Why Quantum Computing Inc. (QUBT) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Quantum Computing Inc. (NASDAQ:QUBT) stands against other Friday's best-performing stocks. Quantum Computing surged by 15.81 percent on Friday to end at $13.70 apiece as investors cheered the company's upgraded rating from an investment firm. In its market note, Ascendiant Capital Markets maintained its 'buy' recommendation on Quantum Computing Inc.'s (NASDAQ:QUBT) stock, while raising its price target to $22 from $14 previously. A data analyst pouring over a chart, the intricacies of its lines being revealed. The new price target represented a 60.6 percent upside from the company's latest closing price. In the first quarter of the year, Quantum Computing Inc. (NASDAQ:QUBT) swung to a net income attributable to shareholders of $16.98 million from a $6.4 million net loss in the same period last year, primarily driven by a $23.6 million non-cash gain on the mark-to-market valuation of the company's warrant liability as a result of its merger with QPhoton in June 2022. Revenues, on the other hand, rose by 44 percent to $39,000 from $27,000 in the same period last year. Overall, QUBTranks 3rd on our list of Friday's best-performing stocks. While we acknowledge the potential of QUBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
